Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444682 | 1.00 | EPHX2 (0.48) | EPHX2GRM4NAMPTALDH1A1L3MBTL1 | |
| SCHEMBL1444681 | 1.00 | EPHX2 (0.48) | EPHX2GRM4NAMPTALDH1A1L3MBTL1 | |
| SCHEMBL12005197 | 0.87 | EPHX2 (0.45) | EPHX2NAMPTKMT2AMEN1NPC1 | |
| SCHEMBL12005199 | 0.87 | EPHX2 (0.45) | EPHX2NAMPTKMT2AMEN1NPC1 | |
| SCHEMBL6865017 | 0.87 | EPHX2 (0.45) | EPHX2NAMPTKMT2AMEN1NPC1 | |
| SCHEMBL12005319 | 0.86 | EPHX2 (0.49) | EPHX2NAMPTALDH1A1L3MBTL1USP30 | |
| SCHEMBL12005322 | 0.86 | EPHX2 (0.49) | EPHX2NAMPTALDH1A1L3MBTL1USP30 | |
| SCHEMBL6863169 | 0.86 | EPHX2 (0.49) | EPHX2NAMPTALDH1A1L3MBTL1USP30 | |
| SCHEMBL6863390 | 0.85 | EPHX2 (0.46) | EPHX2NAMPTALDH1A1 | |
| SCHEMBL6863159 | 0.85 | EPHX2 (0.46) | EPHX2NAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | EPHX2 3610/4885GRM4 759/4885NAMPT 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.